These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23452882)

  • 21. No consensus on withholding angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before spinal anaesthesia.
    Bøgebjerg MK
    Dan Med J; 2012 Dec; 59(12):A4543. PubMed ID: 23290284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In patients with chronic diabetic nephropathy, do angiotensin-converting enzyme inhibitors (ACEI) have greater renal protective effect as compared to angiotensin receptor blockers (ARB)?
    Tucker S; Chen Y; Abell R
    J Okla State Med Assoc; 2013 Jul; 106(7):294-5. PubMed ID: 24032256
    [No Abstract]   [Full Text] [Related]  

  • 23. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ACE inhibitors continue to be first choice in the treatment of heart failure patients].
    Gadsbøll N; Pedersen CT
    Ugeskr Laeger; 2013 May; 175(22):1566-8. PubMed ID: 23721841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 27. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical inquiries. Which combination drug therapies are most effective for hypertension?
    Crawford P; Dy D; Carney M
    J Fam Pract; 2011 Nov; 60(11):684-6. PubMed ID: 22049354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105
    [No Abstract]   [Full Text] [Related]  

  • 31. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National guidelines for the management of absolute cardiovascular disease risk.
    O'Callaghan CJ; Rong P; Goh MY
    Med J Aust; 2014 May; 200(8):454, 456. PubMed ID: 24794600
    [No Abstract]   [Full Text] [Related]  

  • 33. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG; Christie N
    Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Of fads, fashion, surrogate endpoints and dual RAS blockade.
    Messerli FH; Staessen JA; Zannad F
    Eur Heart J; 2010 Sep; 31(18):2205-8. PubMed ID: 20685681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
    Abdellatif AA
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of ARB on prevention of atherosclerosis].
    Aoyama T; Minatoguchi S
    Nihon Rinsho; 2011 Jan; 69(1):92-9. PubMed ID: 21226267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
    Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.